CQ31

CQ31 (0.0152-100 μM; 24 h) induces CASP1-dependent cytotoxicity in wild-type MV4;11 cells with an IC₅₀ of 3.8 μM, but exerts no cytotoxic effect on CASP1-knockout MV4;11 cells^[1].
CQ31 (6.25 μM; 6 h) induces CARD8- and CASP1-dependent lytic cell death as well as caspase-1-dependent pyroptosis in wild-type MV4;11 cells, but exerts no such effects in CASP1-knockout or CARD8-knockout MV4;11 cells^[1][2].
CQ31 (20 μM; 24 h) induces CARD8-dependent pyroptosis (cell death, LDH release, GSDMD cleavage) in wild-type OCI-AML2 and THP-1 cells, but shows no such effect in CARD8-knockout cells, and induces pyroptosis (GSDMD cleavage) in human primary resting T cells^[1].
CQ31 (20 μM; 24 h) induces pyroptosis in THP-1 cells by inhibiting PEPD and XPNPEP1, which in turn suppresses downstream DPP8/9 and activates the CARD8 inflammasome^[1].
CQ31 (20 μM; 6 h) disrupts the CARD8-DPP9 ternary complex, induces CARD8-dependent pyroptosis in HEK 293T cells analyzed by dTAG, and inhibits the enzymatic activity of DPP8/9 in HEK 293T cells^[1][2].
CQ31 inhibits prolinase activity in THP-1 cell lysates in a dose-dependent manner, and completely blocks the cleavage of Ala-Pro dipeptide^[2].
CQ31 (30 min) selectively stabilizes PEPD in HEK 293T cell lysates in CETSA assays, with no effect on DPP9 or NPEPPS^[2].
CQ31 (10 μM; 24 h) induces pyroptosis in resting human primary T cells, which is evidenced by the cleavage of GSDMD^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.